India halts production at factory linked to Gambia deaths

[October 12, 2022]  By Tanvi Mehta

NEW DELHI (Reuters) -Indian authorities have halted all production at a factory of Maiden Pharmaceuticals, a state minister said on Wednesday, after a WHO report that the medicine may be linked to the deaths of dozens of children in Gambia.

The health minister in Haryana state, Anil Vij, said that authorities inspected a Maiden factory near the town of Sonepat in the state and found 12 violations of good practices.

"Keeping this in view, the entire production of the company has been banned and notice has also been issued," Vij said.

The WHO issued a medical product alert last week asking regulators to remove Maiden Pharma goods from the market.

The WHO said that laboratory analysis of four Maiden products - Promethazine Oral Solution, Kofexmalin Baby Cough Syrup, Makoff Baby Cough Syrup and Magrip N Cold Syrup - had "unacceptable" amounts of diethylene glycol and ethylene glycol, which can be toxic and lead to acute kidney injury.

Gambian police, in a preliminary investigation report on Tuesday, said that the deaths of 69 children from acute kidney injury was linked to the cough syrups made in India and imported via a U.S.-based company.

It is one of the worst such incidents involving drugs from India, often dubbed a "pharmacy of the world".

Authorities are waiting for test results on samples of three Maiden Pharma drugs which have been sent to the Central Drug Laboratory in the eastern city of Kolkata, Vij added.

News website Moneycontrol earlier quoted the Haryana drugs controller as saying in a report that Maiden did not perform quality testing of propylene glycol, diethylene glycol and ethylene glycol, while certain batches of propylene glycol did not have the manufacturing and expiry dates.

Logo of the Maiden Pharmaceuticals Ltd. company is seen on a board outside their office in New Delhi, India, October 6, 2022. REUTERS/Anushree Fadnavis

Diethylene glycol and ethylene glycol are used in antifreeze and brake fluids and other industrial applications but also as a cheaper alternative in some pharmaceutical products to glycerine, a solvent or thickening agent in many cough syrups.

Maiden executive Naresh Kumar Goyal declined to comment. He told Reuters last week that the company was trying to find out from its buyer what had happened in Gambia.

Maiden says on its website it has an annual production capacity of 2.2 million syrup bottles, 600 million capsules, 18 million injections, 300,000 ointment tubes and 1.2 billion tablets at three factories.

It said it sells its products domestically and exports to countries in Asia, Africa and Latin America.

The cough syrups had been approved for export only to Gambia, India says, although the WHO says they may have gone elsewhere through informal markets.

India's health ministry said last week that samples of all four Maiden products that had been exported to Gambia had been sent for testing to a federal laboratory and the results would "guide the further course of action as well as bring clarity on the inputs received/to be received from WHO."

The WHO did not respond to requests for comment.

(Reporting by Tanvi Mehta and Krishna Das; Editing by Christopher Cushing, Raju Gopalakrishnan, Kirsten Donovan)

[© 2022 Thomson Reuters. All rights reserved.]  This material may not be published, broadcast, rewritten or redistributed.  Thompson Reuters is solely responsible for this content.